Actively Recruiting
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
Led by PlaqueTec Ltd · Updated on 2026-04-03
300
Participants Needed
4
Research Sites
228 weeks
Total Duration
On this page
Sponsors
P
PlaqueTec Ltd
Lead Sponsor
R
Royal Papworth Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest. Using the data generated from extensive analysis of the blood samples, key biomarker data will be generated that will close a knowledge gap and facilitate the development of tailored treatments for coronary artery disease.
CONDITIONS
Official Title
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older and able to provide informed consent
- Clinical evidence of obstructive coronary artery disease
- Scheduled for elective coronary angiography with or without proceeding for stable angina
- Scheduled for elective PCI for stable angina with known bystander disease
- Scheduled for angiography with or without proceeding for troponin-negative unstable angina
- Suitable lesion identified that meets angiographic criteria for LBS deployment
- Cardiologist comfortable to deploy OCT and LBS on study lesion before PCI on any lesion
You will not qualify if you...
- Myocardial infarction within 30 days of procedure
- Chronic renal failure with eGFR less than 30 ml/min/1.73m2
- Allergy to contrast dye
- Hypotension, shock, or hemodynamic instability
- Ventricular arrhythmia
- Chronic heart failure NYHA class 3 or higher or left ventricular ejection fraction 30% or less
- Immunocompromised or receiving immunosuppressant therapy
- Any active disease making the subject unsuitable or life expectancy less than 1 year
- Active infection or sepsis requiring antibiotics or significant CRP elevation
- Active systemic inflammatory condition
- Inability to receive anticoagulants or antiplatelets or bleeding disorder
- Pregnancy
- High clinical risk or deemed unsuitable for the procedure by treating clinician
- Target lesion in left main coronary artery
- Unsuitable coronary anatomy including vessel tortuosity over 45 degrees, moderate/severe calcification, or ostial disease
- Presence of thrombus in the target vessel
- Prior PCI, stent, or graft in the vessel identified for LBS sampling
- No clinical indication for PCI or pressure wire assessment on any lesion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Royal Bournemouth Hospital
Bournemouth, United Kingdom
Actively Recruiting
2
Bristol Heart Institute
Bristol, United Kingdom
Actively Recruiting
3
Royal Papworth Hospital
Cambridge, United Kingdom
Actively Recruiting
4
Norfolk and Norwich Hospital
Norwich, United Kingdom
Actively Recruiting
Research Team
C
Clinical Project Manager
CONTACT
P
PlaqueTec General Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here